Browsing by Author "Zahurin Mohamed"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    Prevalence of pharmacogenomic variants in 100 pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm)
    (2021-12-01) Chakkaphan Runcharoen; Koya Fukunaga; Insee Sensorn; Nareenart Iemwimangsa; Sommon Klumsathian; Hang Tong; Nam Sy Vo; Ly Le; Tin Maung Hlaing; Myo Thant; Shamsul Mohd Zain; Zahurin Mohamed; Yuh Fen Pung; Francis Capule; Jose Nevado; Catherine Lynn Silao; Zeina N. Al-Mahayri; Bassam R. Ali; Rika Yuliwulandari; Kinasih Prayuni; Hilyatuz Zahroh; Dzul Azri Mohamed Noor; Phonepadith Xangsayarath; Dalouny Xayavong; Sengchanh Kounnavong; Somphou Sayasone; Zoe Kordou; Ioannis Liopetas; Athina Tsikrika; Evangelia Eirini Tsermpini; Maria Koromina; Christina Mitropoulou; George P. Patrinos; Aumpika Kesornsit; Angkana Charoenyingwattana; Sukanya Wattanapokayakit; Surakameth Mahasirimongkol; Taisei Mushiroda; Wasun Chantratita; Faculty of Medicine, YARSI University; YARSI University; School of Pharmaceutical Sciences, Universiti Sains Malaysia; International University,Vietnam National University Ho Chi Minh City; The University of Nottingham Malaysia Campus; University of the Philippines Manila; University of the Philippines College of Medicine; College of Medicine and Health Sciences United Arab Emirates University; School of Health Sciences; Universiti Malaya; Riken; Faculty of Medicine Ramathibodi Hospital, Mahidol University; Thailand Ministry of Public Health; Mahidol University; Defence Services Medical Research Centre; Defence Services Medical Academy; Vingroup Big Data Institute; Lao Tropical and Public Health Institute; The Golden Helix Foundation; National Center for Laboratory and Epidemiology
    Pharmacogenomics can enhance the outcome of treatment by adopting pharmacogenomic testing to maximize drug efficacy and lower the risk of serious adverse events. Next-generation sequencing (NGS) is a cost-effective technology for genotyping several pharmacogenomic loci at once, thereby increasing publicly available data. A panel of 100 pharmacogenes among Southeast Asian (SEA) populations was resequenced using the NGS platform under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm). Here, we present the frequencies of pharmacogenomic variants and the comparison of these pharmacogenomic variants among different SEA populations and other populations used as controls. We investigated the different types of pharmacogenomic variants, especially those that may have a functional impact. Our results provide substantial genetic variations at 100 pharmacogenomic loci among SEA populations that may contribute to interpopulation variability in drug response phenotypes. Correspondingly, this study provides basic information for further pharmacogenomic investigations in SEA populations.
  • No Thumbnail Available
    PublicationMetadata only
    Success stories in genomic medicine from resource-limited countries
    (2015-01-01) Konstantinos Mitropoulos; Hayat Al Jaibeji; Diego A. Forero; Paul Laissue; Ambroise Wonkam; Catalina Lopez-Correa; Zahurin Mohamed; Wasun Chantratita; Ming Ta Michael Lee; Adrian Llerena; Angela Brand; Bassam R. Ali; George P. Patrinos; The Golden Helix Foundation; Maastricht University; College of Medicine and Health Sciences United Arab Emirates University; Universidad Antonio Nariño; Universidad del Rosario; University of Cape Town, Faculty of Health Sciences; Genome Quebec; University of Malaya; Mahidol University; Riken; Academia Sinica, Institute of Biomedical Sciences; Universidad de Extremadura; Panepistimion Patron
    © 2015 Mitropoulos et al. In recent years, the translation of genomic discoveries into mainstream medical practice and public health has gained momentum, facilitated by the advent of new technologies. However, there are often major discrepancies in the pace of implementation of genomic medicine between developed and developing/resource-limited countries. The main reason does not only lie in the limitation of resources but also in the slow pace of adoption of the new findings and the poor understanding of the potential that this new discipline offers to rationalize medical diagnosis and treatment. Here, we present and critically discuss examples from the successful implementation of genomic medicine in resource-limited countries, focusing on pharmacogenomics, genome informatics, and public health genomics, emphasizing in the latter case genomic education, stakeholder analysis, and economics in pharmacogenomics. These examples can be considered as model cases and be readily replicated for the wide implementation of pharmacogenomics and genomic medicine in other resource-limited environments.